What Depression Does to Brain Chemistry

The most familiar story about depression involves serotonin: not enough of it, and mood suffers. That account is not wrong, but it is incomplete. Depression disrupts multiple neurotransmitter systems simultaneously, and the downstream consequences extend well beyond how a person feels on a given day.

Among the most significant changes is what happens to BDNF (brain-derived neurotrophic factor), a protein that supports the growth, survival, and maintenance of neurons (brain cells). In people with depression, BDNF levels are often markedly reduced. This matters because BDNF is essentially the brain’s maintenance crew: without adequate levels, neurons in mood-regulating regions begin to atrophy, synaptic connections weaken, and the brain’s capacity to adapt and recover is compromised. Research has shown that ketamine directly increases BDNF, which may explain part of its rapid antidepressant effect (National Institutes of Health).

The hippocampus, a brain region central to memory formation and emotional regulation, is particularly vulnerable to these changes. Studies show that prolonged depression can actually reduce hippocampal volume, contributing to the memory difficulties and cognitive fog that many patients describe alongside low mood (National Institutes of Health). For Silicon Valley professionals who rely on sharp thinking, this aspect of depression’s neurological footprint is often deeply disruptive.

The Glutamate Gap That SSRIs Don’t Fill

First-line antidepressants, SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors), work by increasing the availability of serotonin and norepinephrine at synapses. They help a significant portion of people with depression, and we respect their role in treatment (National Institutes of Health). But they operate on a specific subset of the brain’s chemistry, and for patients whose depression involves substantial glutamate system dysregulation, serotonin-targeted treatment may simply not be addressing the right problem.

Glutamate is the brain’s primary excitatory neurotransmitter, it drives the vast majority of signaling between neurons. When the glutamate system is dysregulated, as appears to be the case in many forms of treatment-resistant depression, the brain loses some of its capacity for neuroplasticity: the ability to form new connections, reorganize existing pathways, and recover from damage. This is the gap that has made a growing number of clinicians and patients look past the standard antidepressant toolkit.

At Soft Reboot Wellness, Dr. Sara Herman, a Harvard-trained anesthesiologist who has guided more than 10,000 patients through anesthesia and ketamine therapy, built our practice around this understanding. The patients who find their way to us have frequently tried multiple antidepressants, often for years, and still feel stuck. Their experience is not a failure of willpower; it reflects a biological reality about which neurotransmitter systems their depression is actually engaging.

How Neuroplasticity Becomes the Target

Neuroplasticity, the brain’s ability to reorganize itself by forming new neural connections, is not a static trait. It can be increased or decreased by environment, stress, illness, and treatment. Chronic depression is one of the more reliable ways to suppress it; effective treatment for depression is one of the more reliable ways to restore it.

Research shows that ketamine promotes neuroplasticity in ways that standard antidepressants do not, and does so rapidly, changes that SSRIs typically require weeks to approximate can appear within hours of a ketamine infusion (National Institutes of Health). This speed is clinically meaningful. For someone in the grip of severe depression, a week matters. For someone who has been waiting for months across multiple medication trials, the prospect of a different timeline is significant.

The mechanism behind this rapid effect runs through NMDA receptor blockade and the subsequent release of glutamate in a pattern that activates neuroplasticity pathways. In plain terms: ketamine briefly disrupts the brain’s usual signaling, and when that disruption resolves, the brain rebuilds connections in a healthier pattern. It is a reset, not a permanent fix achieved in a single session, but a meaningful opening that, with appropriate integration support, can be built upon.

What This Means for Treatment-Resistant Depression

For patients who have not responded to two or more antidepressant trials, the neuroscience strongly suggests the problem is not that they haven’t found the right serotonin medication. The problem may be that the serotonin system is not the primary driver of their depression at all.

Our IV ketamine infusions at Soft Reboot Wellness target the glutamate system directly, bypassing the serotonin pathway entirely and addressing the neuroplasticity deficit that standard medications leave untouched. A standard induction series involves four to six infusions over four to six weeks, with the protocol personalized to your response. We use the Osmind EHR platform for mood tracking throughout, so progress is documented rather than impressionistic. For patients who want to use the neuroplastic window opened by ketamine for deeper psychological work, our ketamine-assisted psychotherapy (KAP) program adds a preparation session and integration coaching.

We also work closely with patients’ existing treatment teams. If you have a psychiatrist or therapist, we coordinate with them, with your permission, because the neurobiological changes ketamine may produce are best consolidated through ongoing therapeutic work. Results vary by individual, and we encourage you to discuss whether ketamine therapy is appropriate for your specific history with your current healthcare provider.

Addressing the Fear of Starting Something New

One barrier we hear from patients often is not skepticism about the science. It is the exhaustion that comes from having tried things before and having them not work. After multiple medication trials, hope becomes a liability that feels too expensive to extend again.

We understand that. Dr. Herman and our team approach every new patient with the awareness that they are arriving with a history, not just a diagnosis. The initial intake process is designed to give us a thorough picture of what you have tried, for how long, and how you responded, so our recommendations are grounded in your actual trajectory, not a generic protocol. Treatment is not appropriate for everyone, and we will tell you honestly if we do not think we are the right fit.

The cost of ketamine therapy is a real consideration. IV ketamine for mental health is an off-label treatment, and insurance coverage is not standard. We recommend contacting our team at hello@softrebootwellness.com or 650-419-3330 to discuss the financial realities before your consultation, so there are no surprises on either side of the conversation.

Frequently Asked Questions

Can depression actually shrink your brain? Research suggests prolonged depression is associated with reduced volume in the hippocampus and other mood-regulating regions, likely due to the neurotoxic effects of chronic stress hormones and reduced BDNF levels (National Institutes of Health). These changes are not necessarily permanent, effective treatment, including approaches that promote neuroplasticity, may help restore some of this lost volume over time. Results vary by individual.

Why do antidepressants take so long to work if depression is a brain chemistry problem? SSRIs and SNRIs modulate neurotransmitter availability gradually, and the downstream structural changes that correspond with symptom improvement, including neuroplasticity shifts, take weeks to develop. The delay is a function of how those medications work at the synaptic level. Ketamine’s mechanism differs: it triggers a rapid glutamate release and neuroplasticity cascade that can produce antidepressant effects much faster, often within hours of infusion (National Institutes of Health).

Does everyone with depression have glutamate dysregulation? Not necessarily. Depression is not a single condition with a single mechanism. Glutamate dysregulation appears to be more prominent in treatment-resistant presentations, people who have not responded to serotonin-targeting medications. This is part of why we conduct a thorough review of your treatment history before recommending IV ketamine therapy.

How does cognitive fog from depression relate to brain changes? The memory and concentration difficulties many people experience with depression are tied to the same neurobiological changes that affect mood, particularly reduced hippocampal function and BDNF depletion. Effective treatment that addresses these underlying mechanisms may improve cognitive symptoms alongside mood, though results vary significantly between individuals.

Key Takeaways

• Depression produces measurable changes in brain chemistry and structure, including reduced BDNF, hippocampal atrophy, and glutamate system dysregulation. It is not simply a mood state.
• Standard antidepressants target the serotonin and norepinephrine systems; they may not adequately address glutamate dysregulation, which is common in treatment-resistant presentations.
• Neuroplasticity, the brain’s capacity to form new connections, is suppressed by chronic depression and can be rapidly restored by ketamine infusion.
• Our IV ketamine therapy at Soft Reboot Wellness in Menlo Park directly targets the glutamate-neuroplasticity pathway that many patients have not yet addressed.
• Results vary by individual; treatment candidacy is determined through a thorough medical and psychiatric review.

If your depression has not responded the way you hoped to standard treatment, the neuroscience suggests you are not broken, you may simply need treatment that works on a different system. We are glad to talk through whether that is something we can help with. Call us at 650-419-3330 or email hello@softrebootwellness.com to start the conversation.

References

1. Mayo Clinic. Symptoms and causes of major depressive disorder. https://www.mayoclinic.org/diseases-conditions/depression/symptoms-causes/syc-20356007
2. National Institutes of Health. Ketamine promotes neuroplasticity, the brain’s ability to form new neural connections, which may explain its rapid and sustained antidepressant effects. https://pmc.ncbi.nlm.nih.gov/articles/PMC8190578/
3. National Institutes of Health. Ketamine has been shown to increase brain-derived neurotrophic factor (BDNF), a protein essential for neuron growth and long-term mood regulation. https://pubmed.ncbi.nlm.nih.gov/39684808/
4. National Institutes of Health. Research documents the efficacy and limitations of SSRIs as a first-line treatment for depression and anxiety. https://pmc.ncbi.nlm.nih.gov/articles/PMC8395812/
5. National Institutes of Health. Research shows depression can impair memory and cognitive function, which may be improved with effective treatment. https://pmc.ncbi.nlm.nih.gov/articles/PMC5835184/

Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. Treatment for depression, including IV ketamine therapy, should only be pursued under the supervision of a licensed medical provider familiar with your full medical and psychiatric history. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.

Reviewed by Dr. Sara Herman

The post How Depression Changes Your Brain: The Neuroscience Explained appeared first on Soft Reboot Wellness.

How Ketamine Differs From Classical Psychedelics

Most people think of psychedelics in terms of substances like psilocybin or LSD, which work primarily by activating serotonin 2A receptors, a specific docking site on brain cells involved in perception and mood. Ketamine does something different. Its primary mechanism involves blocking NMDA receptors (N-methyl-D-aspartate receptors), which are part of the glutamate system, the brain’s main excitatory neurotransmitter network (National Institutes of Health). Rather than flooding the serotonin system, ketamine modulates glutamate transmission, triggering a cascade of downstream effects that researchers now understand to include rapid antidepressant action and new neural connection formation.

That distinction is not merely academic. It explains why ketamine can produce perceptual changes at therapeutic doses without fitting neatly into the classical psychedelic category. Some researchers classify it as a “dissociative,” others as a “psychedelic-adjacent” compound, and a growing number argue it belongs in its own class entirely. At Soft Reboot Wellness, Dr. Sara Herman and Dr. Natasha work with patients who have often spent years trying serotonin-targeting medications without adequate relief, patients for whom the glutamate pathway may be the missing piece.

The Psychedelic Experience Question

Even if the receptor mechanism differs, ketamine at therapeutic doses can produce experiences that overlap with what people describe in psychedelic-assisted therapy: altered perception of time, a sense of the mind loosening its grip on habitual thoughts, and occasionally vivid inner imagery. This is not a side effect to be managed. It is, in many respects, part of why the treatment works.

Research supports the integration of psychotherapy with ketamine, showing the combination may produce more durable and meaningful outcomes than ketamine alone (National Institutes of Health). This is precisely why our ketamine-assisted psychotherapy (KAP) program at Soft Reboot Wellness pairs in-office infusion sessions with preparation and integration coaching. Dr. Herman holds an Advanced Certificate in Psilocybin-Assisted Therapy from the Integrative Psychiatry Institute and has completed training in Internal Family Systems (IFS) combined with ketamine-assisted psychotherapy, credentials that reflect a genuine commitment to psychedelic medicine as a therapeutic discipline, not just a pharmacological one.

Why the Classification Matters for Patients

Patients searching “is ketamine a psychedelic” are often asking a more personal question underneath that one: will this feel strange, and is that strangeness safe? Both are fair concerns, and we take them seriously.

The perceptual effects of IV ketamine at therapeutic doses are time-limited, occur within a supervised clinical setting, and resolve completely by the time patients leave. Dr. Herman personally provides and monitors all treatment sessions. The dose used in mental health treatment is a fraction of what is used in surgical anesthesia, and the clinical environment at our Menlo Park clinic is designed for comfort and safety throughout. Vital signs are monitored continuously, and patients are never left alone during their infusion.

What the altered state offers, when approached with intention, is a window. Research on how psychedelic-type treatments promote healing suggests these compounds create conditions for neuroplasticity, the brain’s capacity to form new neural connections, by temporarily quieting entrenched patterns of thought and self-criticism (National Institutes of Health). For patients with treatment-resistant depression, anxiety, or PTSD, that window can be genuinely significant.

How Soft Reboot’s Approach Reflects the Science

We did not land on our current model by accident. Our practice is built around the understanding that ketamine’s mechanism (glutamate modulation, NMDA receptor blockade, downstream neuroplasticity) offers something that decades of serotonin-focused treatment have not fully delivered for a substantial portion of patients (Johns Hopkins Bloomberg School of Public Health). That is not a criticism of antidepressants; SSRIs help many people. It is an honest acknowledgment that the brain’s chemistry is more complex than any single system, and that the patients who find their way to us have typically already learned that lesson the hard way.

Our IV ketamine infusions follow a personalized induction protocol, typically four to six infusions over four to six weeks, with the specific number and timing calibrated to your clinical response and the input of your existing treatment providers. We use the Osmind EHR platform for mood tracking throughout your treatment so both you and your care team can see your progress objectively. Each infusion is paired with preparation and integration coaching as part of our ketamine-assisted psychotherapy (KAP) program.

Addressing the Cost and Scheduling Reality

Ketamine therapy is a meaningful financial commitment, and we want to be direct about that. IV ketamine for mental health conditions is considered off-label use, meaning it is an established treatment whose mental health applications have not yet received formal FDA approval for specific psychiatric diagnoses, and insurance coverage is inconsistent. We recommend contacting our team directly to discuss what financial options are available to you before your consultation.

The initial consultation at Soft Reboot Wellness begins by calling or emailing us directly. We send you an intake packet, Dr. Herman reviews it, and then determines whether to schedule a consultation. If you have an existing psychiatrist, therapist, or prescriber, we actively coordinate with them, with your consent, because we believe integrative care produces better outcomes than any single provider working in isolation. Results vary by individual, and we encourage you to discuss all options with your healthcare provider before deciding whether ketamine therapy is right for you.

Frequently Asked Questions

If ketamine isn’t technically a psychedelic, why does it sometimes produce visual or perceptual effects? Ketamine’s dissociative properties at therapeutic doses can produce altered sensory experiences, mild perceptual shifts, a floating or dreamlike quality, or vivid imagery, even though its mechanism differs from classical psychedelics. These effects occur because ketamine affects multiple neurotransmitter systems, not just glutamate. They are temporary, resolve fully within hours, and occur within a monitored clinical environment at our Menlo Park clinic.

Is ketamine therapy the same as recreational ketamine use? No. The dose, delivery method, clinical setting, and intent are entirely different. Therapeutic ketamine infusions are administered intravenously at sub-anesthetic doses by a licensed physician in a clinical environment with continuous monitoring. Recreational use involves very different doses, routes, and contexts. Our team screens all candidates medically and psychiatrically before treatment to ensure it is appropriate for each individual.

Does Soft Reboot Wellness offer psilocybin therapy? We do not currently offer psilocybin therapy as a clinical service. Dr. Herman holds an Advanced Certificate in Psilocybin-Assisted Therapy and stays current with the evolving research in this area, but our active treatment offerings are IV ketamine infusions, ketamine-assisted psychotherapy, stellate ganglion block (SGB), and NAD+ infusions.

How does understanding ketamine’s mechanism help me prepare for my session? Knowing that ketamine works through the glutamate system, promoting neuroplasticity and temporarily quieting rigid thought patterns, can help you approach your session with openness rather than anxiety. Many patients find it useful to set a simple intention before their infusion, something they want to reflect on or release, and to plan for rest and reflection afterward. Our integration coaching component is designed specifically to help you make the most of this window.

Can ketamine therapy be combined with my existing antidepressants or therapy? In many cases, yes, and we actively encourage coordination with your existing treatment team. The specifics depend on your medications and history, which we review during your consultation. We do not ask patients to discontinue existing medications without a conversation involving you and your other providers.

Key Takeaways

• Ketamine is not a classical psychedelic, it works primarily through NMDA receptor blockade in the glutamate system, not through serotonin 2A receptor activation.
• The perceptual effects some patients experience during treatment are a product of this multi-system mechanism and are temporary, monitored, and managed within a clinical setting.
• Research supports combining psychotherapy with ketamine to produce more durable outcomes. This is the foundation of our KAP program at Soft Reboot Wellness.
• IV ketamine for mental health is an off-label use, and insurance coverage is not standard; financial details are best discussed directly with our team.
• Results vary by individual, and candidacy is determined through a thorough medical and psychiatric review before any treatment begins.

Whether you think of ketamine as a psychedelic, a dissociative, or simply a medication that works differently than anything you have tried before, what matters most is whether it might help you. At Soft Reboot Wellness, we are here to answer that question honestly, starting with a conversation. Reach us at 650-419-3330 or email hello@softrebootwellness.com to get started.

References

1. National Institutes of Health. Ketamine works by blocking NMDA receptors in the glutamate system, producing rapid antidepressant effects through a mechanism distinct from traditional antidepressants. https://pmc.ncbi.nlm.nih.gov/articles/PMC5148235/
2. Johns Hopkins Bloomberg School of Public Health. Overview of ketamine’s history, from its origins as an anesthetic to its current use as a fast-acting treatment for depression. https://publichealth.jhu.edu/2024/what-to-know-about-ketamine
3. National Institutes of Health. Psychedelic substances promote neuroplasticity, which may underlie their therapeutic effects on mood, trauma, and addiction. https://pmc.ncbi.nlm.nih.gov/articles/PMC9665925/
4. National Institutes of Health. Research supports the integration of psychotherapy with ketamine treatment, showing that the combination may produce more durable and meaningful outcomes than ketamine alone. https://pmc.ncbi.nlm.nih.gov/articles/PMC9207256/

Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. Ketamine therapy should only be pursued under the supervision of a licensed medical provider familiar with your full medical and psychiatric history. Individual results vary. Off-label treatments like IV ketamine for mental health conditions carry risks that should be discussed thoroughly with a qualified provider before beginning. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.

Reviewed by Dr. Sara Herman

The post Is Ketamine a Psychedelic? Understanding the Science Behind Ketamine Therapy appeared first on Soft Reboot Wellness.

The Glutamate System: The Story Standard Care Underemphasizes

When researchers began looking seriously at why antidepressants work for some people and not others, attention shifted toward a neurotransmitter most patients have never heard of: glutamate. Unlike serotonin, which modulates mood as one signal among many, glutamate is the brain’s primary excitatory neurotransmitter, responsible for the vast majority of signaling between neurons (National Institutes of Health). It is involved in learning, memory, synaptic plasticity, and the brain’s ability to reorganize itself in response to experience.

In a healthy brain, glutamate signaling operates within a careful balance. In a depressed brain, that balance is disrupted, and the consequences ripple outward. The NMDA receptor (N-methyl-D-aspartate receptor), which sits at the center of glutamate signaling and plays a central role in synaptic plasticity, begins to malfunction (National Institutes of Health). Synaptic plasticity is the technical term for the brain’s capacity to strengthen or weaken the connections between neurons depending on how they are being used, the mechanism underlying learning, adaptation, and recovery. When NMDA receptor function falters, the brain loses some of this adaptability, and mood regulation suffers in ways that serotonin-targeting medications do not directly address.

This is not a niche theory. It is increasingly the central explanation for why treatment-resistant depression exists at all, and it is the scientific basis for why ketamine, which works primarily through NMDA receptor blockade, has attracted such serious clinical interest over the past two decades. For a deeper look at the brain changes depression produces, see our post on what depression does to the brain.

What Memory Difficulties Are Telling You

Many people with depression report that their cognition changes alongside their mood. Words come more slowly. Concentration requires effort that used to be effortless. Past memories feel dulled or inaccessible. These are not separate symptoms from the depression. They are part of the same underlying neurobiology (National Institutes of Health).

The hippocampus, a brain structure critical to memory formation and retrieval, is particularly sensitive to the stress hormones elevated in chronic depression. Over time, high cortisol (the primary stress hormone) damages neurons in the hippocampus, contributing to the cognitive symptoms that many patients find as debilitating as the emotional ones. For professionals in Silicon Valley, where cognitive performance is closely tied to professional identity and career functioning, this aspect of depression often carries its own separate weight.

Understanding that these cognitive difficulties have a biological basis, that they are not a character issue or a sign of diminished capability, is something we address directly with patients at Soft Reboot Wellness. The brain changes that depression produces are real, measurable, and in many cases reversible with treatment that targets the right systems.

Why SSRIs Leave a Gap for Some Patients

SSRIs, selective serotonin reuptake inhibitors, work by blocking the reabsorption of serotonin into neurons, keeping more of it active in the space between cells. They are a genuine first-line treatment option and help many people significantly (National Institutes of Health). But they do not touch the glutamate system. They do not directly address NMDA receptor dysfunction. And they typically require six to eight weeks before any meaningful clinical effect is evident, a timeline that reflects the slow, indirect path through which serotonin changes eventually influence neuroplasticity. For a detailed comparison of how ketamine and SSRIs differ mechanically, see our post on ketamine versus SSRI treatment.

For a patient whose depression is primarily driven by glutamate dysregulation and reduced synaptic plasticity, this means that even a well-chosen, well-tolerated SSRI at the right dose may simply be pulling a lever that isn’t connected to the problem. This is not a failure of the medication. It is a mismatch between mechanism and condition.

When patients come to us having tried multiple antidepressants without adequate relief, the working hypothesis we start with is not that the next SSRI or SNRI will be the answer. It is that the serotonin system may not be the primary driver of their depression, and that a treatment targeting glutamate and neuroplasticity directly may be what’s been missing.

What the Depressed Brain Needs to Recover

Recovery from depression, real recovery, not just symptom suppression, requires the brain to rebuild the neural architecture that chronic depression has degraded. This means restoring BDNF (brain-derived neurotrophic factor) levels to support neuron health, repairing synaptic connections in mood-regulating circuits, and re-establishing the kind of glutamate system balance that allows the brain to adapt, learn, and regulate emotion effectively.

Treatment that promotes this kind of recovery works differently than treatment that simply modulates neurotransmitter availability. Ketamine, administered as an IV infusion, blocks NMDA receptors transiently and triggers a downstream release of glutamate in a pattern that activates neuroplasticity pathways, essentially jumpstarting the repair process (National Institutes of Health). The effect is fast by psychiatric standards: many patients report meaningful mood changes within hours of their first infusion, with the neuroplastic effects persisting and consolidating in the days that follow.

At Soft Reboot Wellness, a standard ketamine induction series involves four to six IV ketamine infusions over four to six weeks. Dr. Sara Herman, a Harvard-trained anesthesiologist with Advanced Certificate training in psychedelic-assisted therapy, personally provides and monitors all infusion sessions. We track mood progress through the Osmind platform so you and our team can assess your response objectively rather than relying on memory alone. For patients who want to build on the neuroplastic window the infusions open, our ketamine-assisted psychotherapy (KAP) program adds structured preparation and integration work with a certified psychedelic integration coach.

The Scheduling and Cost Questions

We know that for many patients considering ketamine therapy, the questions are not only neurological. They are practical. How disruptive is this to a work schedule? What does it cost, and will insurance cover any of it?

On scheduling: a ketamine infusion session does not require days of recovery. Most patients return to regular activities the following day, and we offer appointment times designed to accommodate demanding professional schedules. To get started, call or email us directly, we send you an intake packet, Dr. Herman reviews it, and then determines whether to schedule a consultation.

On cost: IV ketamine for mental health is considered an off-label treatment, and insurance coverage is inconsistent. We recommend calling us at 650-419-3330 or contacting us at hello@softrebootwellness.com to discuss costs before your consultation so that financial clarity is part of the decision-making process, not an afterthought. Results vary by individual, and we encourage everyone to discuss their options with their healthcare provider before starting.

Frequently Asked Questions

If my depression involves glutamate, why didn’t my doctor tell me that? Glutamate’s role in depression has become much clearer in the research over the past two decades, but it hasn’t yet shifted mainstream prescribing practice in the same way serotonin science did. Most primary care providers and psychiatrists are appropriately focused on first-line serotonin-targeting medications, which help many patients. The glutamate conversation typically becomes relevant when those first-line options have not produced adequate results. We are happy to discuss where your history fits into this picture during a consultation.

Can the cognitive symptoms of depression, the brain fog and memory issues, improve with treatment? Research suggests they can, particularly when treatment addresses the underlying neurobiological disruption rather than just surface symptoms (National Institutes of Health). The hippocampal changes associated with chronic depression are not necessarily permanent, and treatments that promote neuroplasticity, including ketamine, may support cognitive recovery alongside mood improvement. Results vary significantly between individuals.

Is the glutamate system involved in anxiety as well? Yes. The glutamate and NMDA receptor systems are implicated in anxiety disorders as well as depression, which may help explain why patients with comorbid anxiety and depression sometimes see both improve with ketamine treatment. We treat anxiety at Soft Reboot Wellness and assess the full scope of a patient’s condition during the consultation process.

What makes Soft Reboot different from other ketamine clinics in the Bay Area? Our clinical foundation is built on Dr. Herman’s background as a Harvard-trained anesthesiologist with psychedelic medicine credentials and IFS therapy training, a combination that shapes both the safety standards and the integration approach of our practice. We also work actively with patients’ existing care teams, use structured mood tracking, and offer KAP for patients who want the infusion experience embedded in a broader therapeutic framework. We think the neuroplastic window ketamine opens is best used, not just survived.

Key Takeaways

• The depressed brain shows measurable disruptions in glutamate signaling, NMDA receptor function, and neuroplasticity, changes that serotonin-targeting medications do not directly address.
• Cognitive symptoms like brain fog and memory difficulties are part of the same underlying neurobiology as mood symptoms, not separate complaints.
• SSRIs work well for many patients, but do not directly treat glutamate dysregulation, leaving a gap that IV ketamine therapy is specifically designed to fill.
• IV ketamine at Soft Reboot Wellness in Menlo Park targets the NMDA receptor system, promoting rapid neuroplasticity and BDNF restoration.
• Results vary by individual; treatment is initiated following a thorough medical and psychiatric consultation.

Depression’s grip on the brain is real, but so is the brain’s capacity to change when it gets the right input. If you have been trying to feel better using tools that may not be reaching the right systems, we would like to talk with you about what else may be possible. Reach us at 650-419-3330 or email hello@softrebootwellness.com to start the conversation.

References

1. National Institutes of Health. The glutamate neurotransmitter system is the brain’s primary excitatory system and a key pathway through which ketamine produces its therapeutic effects. https://www.ncbi.nlm.nih.gov/books/NBK62187/
2. National Institutes of Health. NMDA receptors play a central role in synaptic plasticity and are the primary target of ketamine’s antidepressant action. https://pmc.ncbi.nlm.nih.gov/articles/PMC9965111/
3. National Institutes of Health. Research shows depression can impair memory and cognitive function, which may be improved with effective treatment. https://pmc.ncbi.nlm.nih.gov/articles/PMC5835184/
4. National Institutes of Health. Research documents the efficacy and limitations of SSRIs as a first-line treatment for depression and anxiety. https://pmc.ncbi.nlm.nih.gov/articles/PMC8395812/
5. National Institutes of Health. Ketamine promotes neuroplasticity, the brain’s ability to form new neural connections, which may explain its rapid and sustained antidepressant effects. https://pmc.ncbi.nlm.nih.gov/articles/PMC8190578/

Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. Treatment for depression and related conditions, including IV ketamine therapy, should only be pursued under the supervision of a licensed medical provider familiar with your full medical and psychiatric history. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.

Reviewed by Dr. Sara Herman

The post Understanding the Depressed Brain: What’s Really Happening Inside appeared first on Soft Reboot Wellness.